REGENERON PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of Directors: Bonnie L. Bassler, Ph.D.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bonnie L. Bassler, Ph.D.”): 87,348,630 for, 18,594,454 against, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class I directors were elected to serve until the 2028 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 188 asset managers below reported 37,205,813 for, 2,469,570 against, 11,027 abstained, 337 not voted.

Showing the 25 largest of 188 asset managers. See all 188 in the interactive database.

Description as filed by funds: Election of Directors: Michael S. Brown, M.D.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael S. Brown, M.D.”): 77,025,558 for, 28,913,874 against, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class I directors were elected to serve until the 2028 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 188 asset managers below reported 32,662,625 for, 7,012,757 against, 11,028 abstained, 337 not voted.

Showing the 25 largest of 188 asset managers. See all 188 in the interactive database.

Description as filed by funds: Election of Directors: Leonard S. Schleifer, M.D., Ph.D.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Leonard S. Schleifer, M.D., Ph.D.”): 99,271,439 for, 6,672,701 against, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class I directors were elected to serve until the 2028 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 188 asset managers below reported 39,574,760 for, 100,622 against, 11,027 abstained, 337 not voted.

Showing the 25 largest of 188 asset managers. See all 188 in the interactive database.

Description as filed by funds: Election of Directors: George D. Yancopoulos, M.D., Ph.D.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: George D. Yancopoulos, M.D., Ph.D.”): 101,367,161 for, 4,089,290 against, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class I directors were elected to serve until the 2028 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 188 asset managers below reported 39,542,090 for, 133,257 against, 11,063 abstained, 337 not voted.

Showing the 25 largest of 188 asset managers. See all 188 in the interactive database.

Description as filed by funds: Proposal to approve an amendment to the Company's Certificate of Incorporation to declassify the board of directors.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“4. Amendment to the Company's Certificate of Incorporation to Declassify the Board of Directors The proposal to amend the Company's Certificate of Incorporation to declassify the board of directors”): 85,711,231 for, 20,226,748 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 – Amendment to the Company's Certificate of Incorporation to Declassify the Board of Directors The proposal to amend the Company's Certificate of Incorporation to declassify the board of directors was approved based upon the following votes:”
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 189 asset managers below reported 39,588,781 for, 27,386 against, 232 abstained, 337 not voted.

Showing the 25 largest of 189 asset managers. See all 189 in the interactive database.

Description as filed by funds: Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal to approve an amendment to Article IV, Section 2(e)(8) of the Certificate of Incorporation

The 105 asset managers below reported 32,327,197 for, 5,000 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.

Description as filed by funds: Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal to approve an amendment to Article VI of the Certificate of Incorporation.

The 105 asset managers below reported 32,327,197 for, 5,000 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.

The 86 asset managers below reported 7,191,210 for, 4,086 against, 10 abstained, 337 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

The 86 asset managers below reported 7,191,210 for, 4,086 against, 10 abstained, 337 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: Proposal to approve on an advisory basis executive compensation.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule ”): 98,781,758 for, 7,100,590 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 29, 2025 was approved based upon the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 185 managers: 39,538,022 for, 47,029 against, 13,132 abstained, 337 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 854 managers: 51,341,048 for, 5,200,271 against, 4,841 abstained, 7,680 not voted, 2,644 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

REGENERON PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the ”): 105,462,255 for, 6,078,716 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was approved based upon the foll…”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 191 asset managers below reported 39,571,341 for, 104,599 against, 11,027 abstained, 337 not voted.

Showing the 25 largest of 191 asset managers. See all 191 in the interactive database.